ERBB2 and neoplasm: Encouraged by the positive result of a phase II trial in which pyrotinib was used in combination with capecitabine in the treatment of HER2-positive metastatic breast cancer [22], we reasoned that the combination may be able to successfully counteract tumor resistance to anti-HER2 mAbs when combined with an anti-HER2 mAb.